City of Hope initiates phase I study to test its first SARS-CoV-2 investigational vaccine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

City of Hope has initiated a phase I clinical trial that will test one of its investigational SARS-CoV-2 vaccines in healthy volunteers between the ages of 18 and 55 who have not had COVID-19.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login